Amgen Asks Fed. Circ. To Review Merck's $2.5B Patent Loss
Amgen is asking the full Federal Circuit to review a decision that wiped out a Merck subsidiary's $2.5 billion verdict in a patent dispute against Gilead Sciences, saying in an amicus...To view the full article, register now.
Already a subscriber? Click here to view full article